Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMDQBTX)

• Drug Name: [3H]quisqualate Drug Info
• Synonyms: Quisqualic acid; QUISQUALIC ACID; Quisqualate; L-Quisqualic acid; 52809-07-1; (+)-Quisqualic acid; UNII-8OC22C1B99; C5H7N3O5; CHEBI:8734; CHEMBL279956; 8OC22C1B99; (2S)-2-amino-3-(3,5-dioxo-1,2,4-oxadiazolidin-2-yl)propanoic acid; 3-(3,5-Dioxo-1,2,4-oxadiazolidin-2-yl)-L-alanine; 2jbk; 1,2,4-Oxadiazolidine-2-propanoic acid, alpha-amino-3,5-dioxo-, (S)-; (S)-2-AMINO-3-(3,5-DIOXO-[1,2,4]OXADIAZOLIDIN-2-YL)-PROPIONIC ACID; 2or4; AC1ODZB5; (S)-2-amino-3-(3,5-dioxo-1,2,4-oxadiazolidin-2-yl)propanoic acid; QUS; SR-01000075471; QUISQUALATE

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 40539
  ChEBI ID: CHEBI:8734
  CAS Number: CAS 52809-07-1
  TTD Drug ID: DMDQBTX

Molecule-Related Drug Atlas

Drug(s) Targeting Metabotropic glutamate receptor 3 (mGluR3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LY404039	DMWZIRJ	Schizophrenia	6A20	Phase 3	[6]
RO-4995819	DMNTC7O	Major depressive disorder	6A70.3	Phase 2	[7]
Oleoyl-estrone	DM0RA8F	Alzheimer disease	8A20	Phase 2	[8]
MP-101	DMYCITZ	Alzheimer disease	8A20	Phase 2	[9]
BCI-838	DMRXDN3	Major depressive disorder	6A70.3	Phase 1	[10]
Pomaglumetad	DMTOLI5	Schizophrenia	6A20	Phase 1	[11]
BCI-632	DMZYCWT	Alzheimer disease	8A20	Phase 1	[12]
PMID25435285-Compound-16	DMKFX2G	N. A.	N. A.	Patented	[13]
PMID25435285-Compound-15	DMHBWNS	N. A.	N. A.	Patented	[13]
PMID25435285-Compound-20	DMG9FYH	N. A.	N. A.	Patented	[13]

Drug(s) Targeting Metabotropic glutamate receptor 1 (mGluR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PF-1913539	DMXEU14	Alzheimer disease	8A20	Discontinued in Phase 3	[14]
AZD8529	DMEQ2N1	Schizophrenia	6A20	Discontinued in Phase 2	[15]
AZD-9272	DMYSBN3	Neuropathic pain	8E43.0	Discontinued in Phase 1	[16]
NPS-2390	DMMRY0Z	Cerebrovascular ischaemia	8B1Z	Preclinical	[17]
A-841720	DMSO8IE	Pain	MG30-MG3Z	Preclinical	[18]
LY-367385	DM98POQ	Neurological disorder	6B60	Terminated	[19]
L-CCG-I	DMPZ8XH	Discovery agent	N.A.	Investigative	[20]
(1S,3R)-ACPD	DM5DOAF	Discovery agent	N.A.	Investigative	[20]
(+)-MCPG	DMG5QJB	Discovery agent	N.A.	Investigative	[21]
PHCCC	DMNJY79	Discovery agent	N.A.	Investigative	[22]

Drug(s) Targeting Metabotropic glutamate receptor 7 (mGluR7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
L-serine-O-phosphate	DMTJ1NH	Discovery agent	N.A.	Investigative	[23]
L-CCG-I	DMPZ8XH	Discovery agent	N.A.	Investigative	[23]
(1S,3R)-ACPD	DM5DOAF	Discovery agent	N.A.	Investigative	[23]
(+)-MCPG	DMG5QJB	Discovery agent	N.A.	Investigative	[23]
MAP4	DMUCE93	Discovery agent	N.A.	Investigative	[23]
MPPG	DMJHQ9T	Discovery agent	N.A.	Investigative	[23]
[3H]LY341495	DMGX0Y8	Discovery agent	N.A.	Investigative	[23]
alpha-methylserine-O-phosphate	DMCIH1X	Discovery agent	N.A.	Investigative	[23]
L-AP4	DMPJFGI	Discovery agent	N.A.	Investigative	[23]
LSP4-2022	DMBWHGP	Discovery agent	N.A.	Investigative	[24]

Drug(s) Targeting Metabotropic glutamate receptor 2 (mGluR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
RO-4995819	DMNTC7O	Major depressive disorder	6A70.3	Phase 2	[7]
Oleoyl-estrone	DM0RA8F	Alzheimer disease	8A20	Phase 2	[8]
MP-101	DMYCITZ	Alzheimer disease	8A20	Phase 2	[9]
JNJ-64281802	DMNMSVX	Dengue	1D20-1D2Z	Phase 2	[25]
BCI-838	DMRXDN3	Major depressive disorder	6A70.3	Phase 1	[10]
Pomaglumetad	DMTOLI5	Schizophrenia	6A20	Phase 1	[11]
BCI-632	DMZYCWT	Alzheimer disease	8A20	Phase 1	[12]
LY-2979165	DM16IX2	Bipolar disorder	6A60	Phase 1	[26]
JNJ-42491293	DMOL9JR	Psychiatric disorder	6E8Z	Phase 1	[27]
ADX71149	DMBUOX4	Epilepsy	8A60-8A68	Phase 1	[28]

Drug(s) Targeting Glutamate receptor ionotropic kainate 1 (GRIK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Topiramate	DM82Z30	Alcohol dependence	6C40.2	Approved	[29]
LY293558	DM4N6EK	Pain	MG30-MG3Z	Phase 2	[30]
NS 1209	DM9EFH0	Epilepsy	8A60-8A68	Phase 2	[31]
NBQX	DMPHZI5	Neurological disorder	6B60	Phase 1	[32]
YM-90K	DMWRT4L	Convulsion	8A68.Z	Discontinued in Phase 2	[32]
[3H]kainate	DMMK7XU	Discovery agent	N.A.	Investigative	[33]
SYM2081	DM30WDL	Discovery agent	N.A.	Investigative	[33]
DNQX	DMQXPA5	Discovery agent	N.A.	Investigative	[34]
dysiherbaine	DM0EBAF	Discovery agent	N.A.	Investigative	[33]
domoic acid	DMYPVO0	Discovery agent	N.A.	Investigative	[33]

Drug(s) Targeting Metabotropic glutamate receptor 8 (mGluR8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
L-serine-O-phosphate	DMTJ1NH	Discovery agent	N.A.	Investigative	[35]
L-CCG-I	DMPZ8XH	Discovery agent	N.A.	Investigative	[35]
(1S,3R)-ACPD	DM5DOAF	Discovery agent	N.A.	Investigative	[36]
MAP4	DMUCE93	Discovery agent	N.A.	Investigative	[37]
MPPG	DMJHQ9T	Discovery agent	N.A.	Investigative	[36]
alpha-methylserine-O-phosphate	DMCIH1X	Discovery agent	N.A.	Investigative	[38]
L-AP4	DMPJFGI	Discovery agent	N.A.	Investigative	[35]
(S)-3,4-DCPG	DMG5BUA	Discovery agent	N.A.	Investigative	[39]
ACPT-I	DM264XN	Discovery agent	N.A.	Investigative	[40]
CPPG	DMVHX5T	Discovery agent	N.A.	Investigative	[37]

Drug(s) Targeting Glutamate carboxypeptidase II (GCPII)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Capromab	DMHERIJ	Prostate cancer	2C82.0	Approved	[41]
PSMA-11 Ga-68	DMWLTU2	Diagnostic imaging	N.A.	Approved	[42]
Lutetium Lu-177 vipivotide tetraxetan	DMQ0IZ6	Prostate cancer	2C82.0	Approved	[43]
177-Lu-PSMA-617	DMX178V	Prostate cancer	2C82.0	Phase 3	[44]
BAY 2315497	DMUHH2G	Prostate cancer	2C82.0	Phase 3	[45]
J 591 Lu-177	DM9XKJU	Prostate cancer	2C82.0	Phase 2	[46]
G-202	DMQR9I8	Adenocarcinoma	2D40	Phase 2	[47]
ATL101	DMYAQV2	Influenza virus infection	1E30-1E32	Phase 2	[48]
99mTc-MIP-1404	DML4GU1	Prostate cancer	2C82.0	Phase 2	[49]
MLN-591RL	DMJHVZC	Prostate cancer	2C82.0	Phase 2	[50]

Drug(s) Targeting Metabotropic glutamate receptor 5 (mGluR5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AFQ056	DMMHSLC	Fragile X syndrome	LD55	Phase 2/3	[51]
ADX-48621	DM6GTMD	Parkinson disease	8A00.0	Phase 2/3	[52]
RG-7090	DMX8JYN	Fragile X syndrome	LD55	Phase 2	[53]
STX-107	DMLNKX7	Autism spectrum disorder	6A02	Phase 2	[54]
ADX10059	DMGVKHQ	Anxiety disorder	6B00-6B0Z	Phase 2	[55]
McN3377	DMTCADJ	Fragile X syndrome	LD55	Phase 1/2	[56]
MK-3328	DMW2O5D	Alzheimer disease	8A20	Phase 1	[57]
[3H]fenobam	DMBOXA1	Allodynia	MB40.1	Phase 1	[58]
RG7342	DMIW5NG	Schizophrenia	6A20	Phase 1	[59]
BMS-984923	DMFNDUL	Alzheimer disease	8A20	Phase 1	[60]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glutamate carboxypeptidase II (GCPII)	TT9G4N0	FOLH1_HUMAN	Inhibitor	[2]
Glutamate receptor ionotropic kainate 1 (GRIK1)	TT0MYE2	GRIK1_HUMAN	Inhibitor	[3]
Metabotropic glutamate receptor 1 (mGluR1)	TTVBPDM	GRM1_HUMAN	Agonist	[4]
Metabotropic glutamate receptor 2 (mGluR2)	TTXJ47W	GRM2_HUMAN	Inhibitor	[5]
Metabotropic glutamate receptor 3 (mGluR3)	TT8A9EF	GRM3_HUMAN	Inhibitor	[5]
Metabotropic glutamate receptor 5 (mGluR5)	TTHS256	GRM5_HUMAN	Inhibitor	[5]
Metabotropic glutamate receptor 7 (mGluR7)	TT0I76D	GRM7_HUMAN	Inhibitor	[5]
Metabotropic glutamate receptor 8 (mGluR8)	TT0IFKL	GRM8_HUMAN	Inhibitor	[5]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1370).
• [2] Structural insight into the pharmacophore pocket of human glutamate carboxypeptidase II. J Med Chem. 2007 Jul 12;50(14):3267-73.
• [3] Chemo-enzymatic synthesis of a series of 2,4-syn-functionalized (S)-glutamate analogues: new insight into the structure-activity relation of ionotr... J Med Chem. 2008 Jul 24;51(14):4093-103.
• [4] Mutational analysis and molecular modeling of the allosteric binding site of a novel, selective, noncompetitive antagonist of the metabotropic glut... J Biol Chem. 2003 Mar 7;278(10):8340-7.
• [5] Excitatory amino acid receptor ligands: resolution, absolute stereochemistry, and enantiopharmacology of 2-amino-3-(4-butyl-3-hydroxyisoxazol-5-yl)... J Med Chem. 1998 Mar 12;41(6):930-9.
• [6] Positive allosteric modulators of the metabotropic glutamate receptor 2 for the treatment of schizophrenia. Expert Opin Ther Pat. 2009 Sep;19(9):1259-75.
• [7] Novel glutamatergic drugs for the treatment of mood disorders. Neuropsychiatr Dis Treat. 2013; 9: 1101-1112.
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] ClinicalTrials.gov (NCT03044249) A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression. U.S. National Institutes of Health.
• [10] Metabotropic glutamate receptor subtype 2 (GRM2; MGLUR2); GRM3 (MGLUR3). SciBX 3(13); doi:10.1038/scibx.2010.413. April 1 2010
• [11] LY-2140023, a prodrug of the group II metabotropic glutamate receptor agonist LY-404039 for the potential treatment of schizophrenia. Curr Opin Investig Drugs. 2010 Jul;11(7):833-45.
• [12] Synthesis, in vitro pharmacology, structure-activity relationships, and pharmacokinetics of 3-alkoxy-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent and selective group II metabotropic glutamate receptor antagonists. J Med Chem. 2004 Aug 26;47(18):4570-87.
• [13] Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
• [14] Pfizer. Product Development Pipeline. March 31 2009.
• [15] Clinical pipeline report, company report or official report of AstraZeneca (2009).
• [16] Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
• [17] Positive and negative modulation of group I metabotropic glutamate receptors. J Med Chem. 2008 Feb 14;51(3):634-47.
• [18] Comparison of the mGluR1 antagonist A-841720 in rat models of pain and cognition. Behav Pharmacol. 2007 Jul;18(4):273-81.
• [19] Anticonvulsant actions of LY 367385 ((+)-2-methyl-4-carboxyphenylglycine) and AIDA ((RS)-1-aminoindan-1,5-dicarboxylic acid). Eur J Pharmacol. 1999 Feb 26;368(1):17-24.
• [20] Characterization of [(3)H]Quisqualate binding to recombinant rat metabotropic glutamate 1a and 5a receptors and to rat and human brain sections. J Neurochem. 2000 Dec;75(6):2590-601.
• [21] [3H]R214127: a novel high-affinity radioligand for the mGlu1 receptor reveals a common binding site shared by multiple allosteric antagonists. Mol Pharmacol. 2003 May;63(5):1082-93.
• [22] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 289).
• [23] Binding of [3H](2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl) glycine ([3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes. Naunyn Schmiedebergs Arch Pharmacol. 2000 Dec;362(6):546-54.
• [24] A novel selective metabotropic glutamate receptor 4 agonist reveals new possibilities for developing subtype selective ligands with therapeutic potential. FASEB J. 2012 Apr;26(4):1682-93.
• [25] Pharmacokinetic and pharmacodynamic characterisation of JNJ-40411813, a positive allosteric modulator of mGluR2, in two randomised, double-blind phase-I studies. J Psychopharmacol. 2015 Apr;29(4):414-25.
• [26] Annual Reports in Medicinal Chemistry. Volume 47, 2012, Page(78).
• [27] Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders. Nat Rev Drug Discov. 2014 Sep;13(9):692-708.
• [28] MGlu2 receptor-mediated modulation of conditioned avoidance behavior in rats. European journal of pharmacology. 01/2014; 727(1).
• [29] Development of medications for alcohol use disorders: recent advances and ongoing challenges. Expert Opin Emerg Drugs. 2005 May;10(2):323-43.
• [30] Pharmacogenetics of new analgesics. Br J Pharmacol. 2011 Jun;163(3):447-60.
• [31] The efficacy of the AMPA receptor antagonist NS1209 and lidocaine in nerve injury pain: a randomized, double-blind, placebo-controlled, three-way crossover study. Anesth Analg. 2009 Apr;108(4):1311-9.
• [32] 4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with... Bioorg Med Chem Lett. 2000 May 15;10(10):1133-7.
• [33] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 450).
• [34] Synthesis of chiral 1-(2'-amino-2'-carboxyethyl)-1,4-dihydro-6,7-quinoxaline-2,3-diones: alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate recep... J Med Chem. 1996 Oct 25;39(22):4430-8.
• [35] Cloning and functional expression of alternative spliced variants of the human metabotropic glutamate receptor 8. Brain Res Mol Brain Res. 1999 Apr 20;67(2):201-10.
• [36] Group III human metabotropic glutamate receptors 4, 7 and 8: molecular cloning, functional expression, and comparison of pharmacological properties in RGT cells. Brain Res Mol Brain Res. 1998 Jan;53(1-2):88-97.
• [37] Constraints on proper folding of the amino terminal domains of group III metabotropic glutamate receptors. Brain Res Mol Brain Res. 2000 Mar 10;76(1):180-90.
• [38] The metabotropic glutamate receptors: structure, activation mechanism and pharmacology. Curr Drug Targets CNS Neurol Disord. 2002 Jun;1(3):297-317.
• [39] (S)-3,4-DCPG, a potent and selective mGlu8a receptor agonist, activates metabotropic glutamate receptors on primary afferent terminals in the neonatal rat spinal cord. Neuropharmacology. 2001 Mar;40(3):311-8.
• [40] Pharmacological characterization of the rat metabotropic glutamate receptor type 8a revealed strong similarities and slight differences with the type 4a receptor. Eur J Pharmacol. 2000 Apr 7;394(1):17-26.
• [41] Synergistic value of single-photon emission computed tomography/computed tomography fusion to radioimmunoscintigraphic imaging of prostate cancer. Semin Nucl Med. 2007 Jan;37(1):17-28.
• [42] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [43] [177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer]. Nuklearmedizin. 2016 Jun 28;55(3):123-8.
• [44] Review of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer. Cureus. 2020 Jun 30;12(6):e8921.
• [45] ClinicalTrials.gov (NCT03724747) Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer. U.S. National Institutes of Health.
• [46] Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013 Sep 15;19(18):5182-91.
• [47] National Cancer Institute Drug Dictionary (drug id 666090).
• [48] Clinical pipeline report, company report or official report of Atlab pharma.
• [49] 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer. J Nucl Med. 2013 Aug;54(8):1369-76.
• [50] Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors. EJNMMI Res. 2015 Apr 29;5:28.
• [51] Metabolism and disposition of the metabotropic glutamate receptor 5 antagonist (mGluR5) mavoglurant (AFQ056) in healthy subjects. Drug Metab Dispos. 2013 Sep;41(9):1626-41.
• [52] Pipeline of Addex Pharma. Addex Pharma. 2009.
• [53] The challenges of clinical trials in fragile X syndrome. Psychopharmacology (Berl) 2014; 231(6): 1237-1250.
• [54] Social Communication is an Emerging Target for Pharmacotherapy in Autism Spectrum Disorder - A Review of the Literature on Potential Agents. J Can Acad Child Adolesc Psychiatry. 2014 February; 23(1):20-30.
• [55] A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and... Gut. 2009 Sep;58(9):1192-9.
• [56] Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
• [57] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 293).
• [58] Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agon... J Pharmacol Exp Ther. 2005 Nov;315(2):711-21.
• [59] Clinical pipeline report, company report or official report of Roche.
• [60] Silent Allosteric Modulation of mGluR5 Maintains Glutamate Signaling while Rescuing Alzheimer's Mouse Phenotypes. Cell Rep. 2017 Jul 5;20(1):76-88.